Butylphthalide soft capsules | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
- Medicine type
- Chemical medicine
- Therapeutic area
- Neurology
- Indications recorded in the public source
- For mild-to-moderate acute ischemic stroke.
- Indication source and scope
- Manufacturer prescribing information for Mainland China. Historical label; subsequent changes may not be included. An approval or revision date is blank or a placeholder; the exact revision date is not confirmed.
- Prescribing-information limitations
- Complete official prescribing information obtained. Mainland China label.
- China availability status
- Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- Overseas status
- Market-by-market verification pending.
- Insurance classification
- Included in national insurance (Category B)
- Insurance edition
- 2025 edition; effective 1 January 2026
- Insurance restrictions
- Restricted to newly occurring acute ischemic stroke when treatment starts within 72 hours of onset; reimbursement is limited to 20 days.
- Insurance period
- 2025-01-01 to 2026-12-31
- Insurance verification notes
- Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.
Sources
- https://www.imm.ac.cn/xycz/sscxyw/0a32de20a1bf44aab45cce49e2b50453.htm
- https://www.nhsa.gov.cn/module/download/downfile.jsp?classid=0&filename=a32f9f2f3fc046afaf08471f87456ce3.pdf
- https://www.e-cspc.com/upload/明星产品/files/恩必普软胶囊说明书.pdf
Open the interactive record, public price references and discussions